DIAGNOS Submits Modified and Updated Health Canada Licence Application for CARA System Platform
BROSSARD, Quebec, June 16, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that it has submitted a modified and updated application for a Class II medical device licence for its proprietary CARA System platform to Health Canada.
BROSSARD, Quebec, June 16, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that it has submitted a modified and updated application for a Class II medical device licence for its proprietary CARA System platform to Health Canada.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.